Preprint / Version 3

How CRISPR/Cas9 Can Be Used to Treat Cystic Fibrosis


  • Nandita Rajagopal Oak Park High School



CRISPR/Cas9, Cystic Fibrosis


From its discovery in the immune systems of prokaryotes, the clustered regularly interspaced short palindromic repeats/CRISPR-associated (CRISPR/Cas9) system has revolutionized gene editing. With these advances in gene editing, there come many potential medical applications of the CRISPR/Cas9 technology to treat genetic diseases. This paper describes methods of using CRISPR/Cas9 to treat the genetic disorder Cystic Fibrosis (CF). CF is caused by a mutated cystic fibrosis transmembrane conductance regulator (CFTR) gene, affecting many of the body’s cells. People carrying this mutation have thick and sticky mucus which can build up in the digestive tract and lungs, leading to severe blockages and damage. These blockages can lead to trouble breathing and a higher possibility of infection. This paper will examine the current cystic fibrosis treatment, including the available drugs and their limitations. CRISPR/Cas9 has the potential to completely cure the disease in one treatment through the modification of the CFTR gene in the patients’ cells. This paper describes delivery mechanisms and mechanistic details of the gene editing process and how it can be applied to cystic fibrosis patients.


Carolyn Brokowski, & Adli, M. (2018). CRISPR ethics: Moral considerations for applications of a powerful tool. J. Mol Bio.

Cyranoski, D. (2019). What’s Next for CRISPR Babies? Nature, 566, 440–442.

De Boeck, K. (2020). Cystic Fibrosis in the year 2020: A disease with a new face. Acta Pediatrica, 109(5).

Firth, A. L., Menon, T., Parker, G. S., Quails, S. J., Lewis, B. M., Ke, E., Dargitz, C. T., Wright, R., Khanna, A., Gage, F. H., & Verma, I. M. (2015). Functional Gene Correction for Cystic Fibrosis in Lung Epithelial Cells Generated From Patient iPSCs. Cell Rep, 12(9), 1385–1390.

Graham, C., & Hart, S. (2021). Expert Opinion on Biological Thoery, 21(6).

Jinek, M., Chylinski, K., Fonfara, I., Hauer, M., Doudna, J. A., & Charpentier, E. (2012). A programmable Dual-RNA-Guided Endonuclease in Adaptive Bacterial Immunity.

Ledford, H. (2019). CRISPR Babies: When will the wolrd be ready? Nature Med, 25.

Martin Newman & Frederick M. Ausubel. (2016). Introduction to Gene Editing and Manipulation Using CRISPR/Cas9 Technology.

Rafeed, M., & Aly Sayed Murad, H. (2017). Cystic fibrosis: Current therapuetic targets and future approaches. Journal of Translational Medicine, 15(84).

Sanchez, A. da S., Paunovska, K., Cristian, A., & Dahlman, J. E. (n.d.). Treating Cystic Fibrosis with mRNA and CRISPR. Human Gene Therapy.

Schwank, G., Koo, B.-K., Sasselli, V., Nieuwenhuis, E. E. S., Beekman, J. M., Clevers, H., Dekkers, J. F., Heo, I., Demircan, T., Sasaki, N., Boymans, S., Cuppen, E., & van der Ent, C. K. (2013). Functional Repair of CFTR by CRISPR?Cas9 in Intestinal Stem Cell Organoids of Cystic Fibrosis Patients. Cell Stem Cell, 13(6), 653–658.

Shinwari, Z. K., Tanveer, F., & Khalil, A. T. (2017). Ethical Issues Regarding CRISPR-mediated Genome Editing. Caister Academic Press.



2022-11-23 — Updated on 2023-01-03